Skip to main content

entX

HardwareAdelaide, AustraliaFounded 2014· One of 1739 Hardware companies tracked by AMPulse

An innovation hub specializing in nuclear science and engineering to develop long-term power systems, life-saving medical isotopes, and clean energy technologies for space, defense, and healthcare.

CEO / Founder
Bryn Jones
Team Size
11-50
Stage
Active
Total Funding
$30.2M
Latest Round
Grant
Key Investors
Foxglove Capital, Australian Government (Department of Industry, Science and Resources), South Australian Government (Economic Recovery Fund)

Technology & Products

Key Products

Nuclear batteries (betavoltaic devices) for space and defense, medical isotopes for cancer treatments, and clean energy technologies (green hydrogen and ammonia).

Technological Advantage

Utilizes proprietary semiconductor deposition and additive manufacturing (3D printing) to integrate radioactive layers into compact frames, significantly increasing energy density compared to traditional methods. Also features the ability to recover valuable isotopes from unconventional sources like mine tailings and waste streams.

Differentiation

Value Proposition

Provides maintenance-free, self-sustaining power for decades in extreme environments and establishes a sovereign, reliable supply chain for critical cancer-fighting isotopes.

How They Differentiate

Proprietary use of additive manufacturing (3D printing) to integrate radioactive layers directly into compact structural frames, enabling higher energy density and durability compared to traditional semiconductor deposition.

Market & Competition

Target Customers

Space agencies (e.g., ASA, NASA), defense contractors, global radiopharmaceutical companies, and heavy industrial firms seeking decarbonization solutions.

Industry Verticals

["Space & Aerospace","Defense","Healthcare (Nuclear Medicine)","Clean Energy","Heavy Industry & Mining"]

Competitors

City Labs; Arkenlight; SHINE Technologies; Betavolt

Growth & Milestones

Growth Metrics

Secured $19.1M+ in government grants alongside $27M in private capital; targeting flight heritage missions for 2026-2027.

Major Milestones

["Rebranded from PhosEnergy to entX in 2023 to reflect a broader nuclear and clean energy focus.","Awarded $2.915M CRC-P Grant in October 2024 for the IsoMedica medical isotope facility.","Collaborated with the University of Adelaide in February 2026 to scale GenX nuclear battery production via additive manufacturing."]

Notable Customers

Australian Space Agency (ASA); Australian Department of Defence; University of Adelaide; ANSTO

https://www.entx.com.au

Recent coverage of entX

Why this company matters

entX is an Australian innovation hub that applies nuclear science and additive manufacturing to create long-duration power systems and medical isotopes. It positions itself as a sovereign capability provider for extreme environments, targeting gaps in space power, defense energy autonomy, and critical medical supply chains. Unlike conventional radioisotope power systems that rely on separate semiconductor layers, entX uses metal AM to integrate radioactive material directly into compact structural frames, increasing energy density and durability.

The company's core products include betavoltaic nuclear batteries for space and defense, medical isotopes for cancer treatments, and clean energy technologies such as green hydrogen and ammonia. Its GenX nuclear battery program, developed with the University of Adelaide, leverages proprietary semiconductor deposition and 3D printing to produce maintenance-free power sources that can operate for decades in harsh conditions. entX also recovers valuable isotopes from unconventional sources like mine tailings and waste streams, using its PhosEnergy and IsoMedica extraction processes.

entX serves space agencies such as the Australian Space Agency and NASA, defense contractors, radiopharmaceutical companies, and heavy industrial firms. It has secured over $30 million in funding from Foxglove Capital and Australian government grants, including a $2.9 million CRC-P grant in 2024 for its IsoMedica medical isotope facility. The company targets flight heritage missions for its power systems by 2026-2027 and competes with firms like City Labs, Arkenlight, and Betavolt.

A key strategic moat is entX's proprietary use of additive manufacturing to embed radioactive layers into structural frames, a method that differs from traditional semiconductor deposition. However, the company faces the challenge of proving reliability in space and defense applications, where qualification cycles are long and risk tolerance is low. Its partnerships with ANSTO and the Australian government provide access to nuclear infrastructure and funding, but scaling production and achieving flight heritage remain open questions.